Rimiducid (AP1903) Clinical Trials

2 actively recruiting trials across 1 location

▲ +1 trial since May 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

M.D. Anderson Cancer Center1
Beijing Biotech1

Indications

Cancer2
B2 Thymoma1
Thymic Carcinoma1
Minimal Residual Disease1
Colorectal Cancer1

Other1 trial

Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma

Phase 1/2

Houston, Texas1 trial

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

MD Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.